Objective: To systematically assess the clinical efficacy and safety of Kanglaite Injection in combination with chemotherapy for cancer pain. Using PICO framework: Population (adult cancer patients ...

The treatment reprograms T cells to hunt down a patient's cancer. The approach could speed treatment and cut costs, but needs more study. With just a single injection, a new treatment transforms ...

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a potential new treatment target for patients with ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

Based on the results from the Phase 3 PALOMA-3 study, Rybrevant Faspro delivered consistent results to Rybrevant, meeting both co-primary pharmacokinetic (PK) endpoints. Data presented at ASCO in 2024 ...

Rybrevant Faspro is a new under-the-skin (subcutaneous) injection form of the cancer medicine Rybrevant (amivantamab). The FDA has now approved it in combination with another medicine called ...